These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37855029)

  • 1. Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer.
    Patell R; Hsu C; Shi M; Grosso MA; Duggal A; Buller HR; Raskob G; Zwicker JI
    Haematologica; 2024 Jun; 109(6):1849-1856. PubMed ID: 37855029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
    Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
    J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
    N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
    Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
    van Es N; Di Nisio M; Bleker SM; Segers A; Mercuri MF; Schwocho L; Kakkar A; Weitz JI; Beyer-Westendorf J; Boda Z; Carrier M; Chlumsky J; Décousus H; Garcia D; Gibbs H; Kamphuisen PW; Monreal M; Ockelford P; Pabinger I; Verhamme P; Grosso MA; Büller HR; Raskob GE
    Thromb Haemost; 2015 Nov; 114(6):1268-76. PubMed ID: 26271200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of cancer-associated venous thromboembolism].
    Di Nisio M
    G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
    Nakamura M; Wang YQ; Wang C; Oh D; Yin WH; Kimura T; Miyazaki K; Abe K; Mercuri M; Lee LH; Segers A; Büller H
    J Thromb Haemost; 2015 Sep; 13(9):1606-14. PubMed ID: 26179767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
    Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
    Abdel-Razeq H; Finianos A; Taher AT
    Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.
    Mulder FI; van Es N; Kraaijpoel N; Di Nisio M; Carrier M; Duggal A; Gaddh M; Garcia D; Grosso MA; Kakkar AK; Mercuri MF; Middeldorp S; Royle G; Segers A; Shivakumar S; Verhamme P; Wang T; Weitz JI; Zhang G; Büller HR; Raskob G
    Thromb Res; 2020 Jan; 185():13-19. PubMed ID: 31733403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.
    Connell NT; Connors JM
    J Thromb Thrombolysis; 2019 Oct; 48(3):382-386. PubMed ID: 31228036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
    Stebler-Fontaine L; Rossel A; Marti C; Righini M; Robert-Ebadi H
    Rev Med Suisse; 2019 Dec; 15(674):2232-2235. PubMed ID: 31804034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
    Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
    Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
    Scheres L; Brekelmans M; Ageno W; Ay C; Büller HR; Eichinger S; Hutten BA; Klok FA; Middeldorp S; Schreiber K; Stach K; Blondon M; Delluc A
    BJOG; 2018 Nov; 125(12):1581-1589. PubMed ID: 29940089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
    Yamashita Y; Morimoto T; Muraoka N; Oyakawa T; Umetsu M; Akamatsu D; Nishimoto Y; Sato Y; Takada T; Jujo K; Minami Y; Ogihara Y; Dohi K; Fujita M; Nishikawa T; Ikeda N; Hashimoto G; Otsui K; Mori K; Sueta D; Tsubata Y; Shoji M; Shikama A; Hosoi Y; Tanabe Y; Chatani R; Tsukahara K; Nakanishi N; Kim K; Ikeda S; Mo M; Yoshikawa Y; Kimura T;
    Circulation; 2023 Nov; 148(21):1665-1676. PubMed ID: 37638968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.